Related Experiment Video

Updated: Aug 16, 2026

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
10:28

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

Estimation of the individual metabolic state and its consideration in optimal pharmacotherapy

W Riess, S Brechbühler, P H Degen

    International Journal of Clinical Pharmacology Research
    |January 1, 1983
    PubMed

    More Related Videos

    Arteriovenous Metabolomics to Measure In Vivo Metabolite Exchange in Brown Adipose Tissue02:55

    Arteriovenous Metabolomics to Measure In Vivo Metabolite Exchange in Brown Adipose Tissue

    Published on: October 6, 2023

    Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics11:02

    Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

    Published on: November 29, 2024

    Related Concept Videos

    Pharmacokinetic Models: Comparison and Selection Criterion01:26

    Pharmacokinetic Models: Comparison and Selection Criterion

    Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
    Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
    Dosage Regimens: Partial Pharmacokinetic Parameters01:01

    Dosage Regimens: Partial Pharmacokinetic Parameters

    It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

    In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
    Pharmacogenetics of Drug Metabolism: Overview01:27

    Pharmacogenetics of Drug Metabolism: Overview

    Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
    Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

    Pharmacokinetic–Pharmacodynamic Relationship: Problems

    The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...